Statin therapy is the first-line pharmacologic treatment for lowering low-density lipoprotein cholesterol (LDL-C) and reducing atherosclerotic cardiovascular disease (ASCVD) risk. However, evidence-based and guideline-recommended therapies continue to be underutilized — even among the highest risk patients. More education is needed to address gaps in ASCVD care, particularly among patients who cannot reach their LDL-C goals with statin therapy alone.
VLN is pleased to launch Cholesterol Conversations, a limited-series podcast discussing the latest guidance on ASCVD management and available treatment options for optimal LDL-C lowering. New data on the efficacy of novel agents and combination therapy is also highlighted.
All content for Cholesterol Conversations is the property of Vasculearn Network and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Statin therapy is the first-line pharmacologic treatment for lowering low-density lipoprotein cholesterol (LDL-C) and reducing atherosclerotic cardiovascular disease (ASCVD) risk. However, evidence-based and guideline-recommended therapies continue to be underutilized — even among the highest risk patients. More education is needed to address gaps in ASCVD care, particularly among patients who cannot reach their LDL-C goals with statin therapy alone.
VLN is pleased to launch Cholesterol Conversations, a limited-series podcast discussing the latest guidance on ASCVD management and available treatment options for optimal LDL-C lowering. New data on the efficacy of novel agents and combination therapy is also highlighted.
ASCVD Management: Making the Case for Nonstatin Therapies
Cholesterol Conversations
21 minutes 25 seconds
2 years ago
ASCVD Management: Making the Case for Nonstatin Therapies
Cholesterol Conversations
Statin therapy is the first-line pharmacologic treatment for lowering low-density lipoprotein cholesterol (LDL-C) and reducing atherosclerotic cardiovascular disease (ASCVD) risk. However, evidence-based and guideline-recommended therapies continue to be underutilized — even among the highest risk patients. More education is needed to address gaps in ASCVD care, particularly among patients who cannot reach their LDL-C goals with statin therapy alone.
VLN is pleased to launch Cholesterol Conversations, a limited-series podcast discussing the latest guidance on ASCVD management and available treatment options for optimal LDL-C lowering. New data on the efficacy of novel agents and combination therapy is also highlighted.
